Your browser doesn't support javascript.
loading
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Peters, S; Dafni, U; Boyer, M; De Ruysscher, D; Faivre-Finn, C; Felip, E; Garrido, P; Girard, N; Guckenberger, M; Haanen, J; Le Pechoux, C; Mornex, F; Ozsahin, M; Paz-Ares, L; Planchard, D; Raben, D; Ramalingam, S; Reck, M; Smit, E; Stahel, R; Stenzinger, A; Swanton, C; Vallone, S; Garassino, M C.
Afiliação
  • Peters S; Oncology Department, Lausanne University and CHUV, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.
  • Dafni U; Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
  • Boyer M; Chris O'Brien Lifehouse, Camperdown, Australia.
  • De Ruysscher D; GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Department of Radiation Oncology (Maastro Clinic), Maastricht, The Netherlands.
  • Faivre-Finn C; Department of Clinical Oncology, The Christie NHS Foundation Trust & University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Felip E; Oncology Department, Vall d'Hebron University, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Garrido P; Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.
  • Girard N; Thorax Institute, Institute Curie, Paris, France.
  • Guckenberger M; Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
  • Haanen J; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Le Pechoux C; Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
  • Mornex F; Université Claude Bernard Lyon1, and Hospices Civils de Lyon, Lyon, France.
  • Ozsahin M; Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO & Universidad Complutense, Madrid, Spain.
  • Planchard D; Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France.
  • Raben D; Marsico Family Endowed Chair of Head and Neck Cancer Research, University of Colorado Cancer Center, Aurora, USA.
  • Ramalingam S; Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, USA.
  • Reck M; LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany.
  • Smit E; Egbert Smit, Department Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Stahel R; Chair Comprehensive Cancer Center Zürich, Universitätspital Zurich, Zurich, Switzerland.
  • Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Swanton C; Cancer Evolution and Genome Stability Laboratory, The Francis Crick Institute and UCL Cancer Institute, UK.
  • Vallone S; Lung Cancer Europe (LuCE), Bern, Switzerland.
  • Garassino MC; Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Ann Oncol ; 30(2): 161-165, 2019 02 01.
Article em En | MEDLINE | ID: mdl-30624547
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprovação de Drogas / Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Ann Oncol Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Aprovação de Drogas / Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Ann Oncol Ano de publicação: 2019 Tipo de documento: Article